Through research we were able to identify an “unmet” need from large and mid cap pharma to dispose of legacy and non core assets. Pharma disposed of these assets to free up production lines for newer higher volume blockbusters, tighten the focus of their therapeutic area or to delever. Noden’s strong management team, global platform and operational experience at onboarding these products made it the ideal platform to address the need of large and mid cap pharma.
In 2020, SCP started thematic research of the outsourced pharma services market, identifying five sub-sectors for deeper deal-focused research. The safety services and pharmacovigilance (“PV”) market was identified as a key target.
Using its research, our team was able to identify the Clario subsidiary, Qinecsa early as a target investment.